OmniComm Systems Acquires EDC Assets of Logos Technologies
8.4.09
Fort Lauderdale, Florida
OmniComm Systems (Fort Lauderdale, FL) has acquired the EDC assets of UK-based Logos Technologies, who has U.S. headquarters in Arlington, VA. The acquisition will be led by OmniComm's UK subsidiary OmniComm Ltd. and provide the parent company with EDC products that cover all aspects of the Phase I process, including subject recruitment, clinical workflow management, and laboratory samplemanagement.
"We are pleased to add the Logos products and operations to the OmniComm team,” said Cornelis F. Wit,
OmniComm's President and CEO, in a company press release. "We believe that the addition of the Logos Phase I products is of importance for OmniComm Systems, as it will broaden the scope of our integrated eClinical solutions offering. Only a very small number of EDC companies specialize in the Phase I market, therefore this acquisition represents animportant addition to our overall corporate growth strategy."
OmniComm reports that the new Logos products will complement their TrialMaster software, which is primarily used in later stage clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
